2. Academic Validation
  3. Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors

Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors

  • J Med Chem. 2015 Jun 25;58(12):5028-37. doi: 10.1021/acs.jmedchem.5b00424.
Jeremy Green 1,  Jingrong Cao 1,  Upul K Bandarage 1,  Huai Gao 1,  John Court 1,  Craig Marhefka 1,  Marc Jacobs 1,  Paul Taslimi 1,  David Newsome 1,  Tomoko Nakayama 1,  Sundeep Shah 2,  Steve Rodems 2
Affiliations

Affiliations

  • 1 †Vertex Pharmaceuticals, Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States.
  • 2 ‡Vertex Pharmaceuticals, Inc., 11010 Torreyana Road, San Diego, California 92121, United States.
PMID: 26039570 DOI: 10.1021/acs.jmedchem.5b00424
Abstract

The Rho kinases (ROCK1 and ROCK2) are highly homologous serine/threonine kinases that act on substrates associated with cellular motility, morphology, and contraction and are of therapeutic interest in diseases associated with cellular migration and contraction, such as hypertension, glaucoma, and erectile dysfunction. Beginning with compound 4, an inhibitor of ROCK1 identified through high-throughput screening, systematic exploration of SAR, and application of structure-based design, led to potent and selective ROCK inhibitors. Compound 37 represents significant improvements in inhibition potency, kinase selectivity, and CYP inhibition and possesses pharmacokinetics suitable for in vivo experimentation.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z